Menu Search
Equities

Bionano Genomics

BNGO*:MEX

Bionano Genomics

Actions
  • Price (MXN)8.50
  • Today's Change0.77 / 9.96%
  • Shares traded2.00
  • 1 Year change-84.24%
  • Beta--
Data delayed at least 20 minutes, as of Sep 17 2024 19:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Bionano Genomics had net income fall 75.34% from a loss of 132.60m to a larger loss of 232.49m despite revenues that grew 29.90% from 27.80m to 36.12m over the same period.
Gross margin28.97%
Net profit margin-557.98%
Operating margin-509.33%
Return on assets-101.86%
Return on equity-138.33%
Return on investment-123.67%
More ▼

Cash flow in USDView more

In 2023, Bionano Genomics increased its cash reserves by 234.15%, or 12.86m. Cash Flow from Financing totalled 113.82m or 315.14% of revenues. In addition the company used 125.18m for operations while cash from investing totalled 24.16m.
Cash flow per share-3.91
Price/Cash flow per share--
Book value per share1.14
Tangible book value per share0.7109
More ▼

Balance sheet in USDView more

Bionano Genomics uses little debt in its capital structure as supported by a debt to capital ratio of 4.55%.
Current ratio1.63
Quick ratio1.11
Total debt/total equity0.0477
Total debt/total capital0.0455
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.